About Anat Stemmer-Rachamimov, MD
Anat Stemmer-Rachamimov, MD, is a faculty member of the C. S. Kubik Laboratory for Neuropathology providing diagnostic services, instruction to trainees on the Neuropathology service through didactic teaching sessions and routine sign-out procedures. She is the co-director of the DFHCC Specialized Histopathology Services Core, co-director of the Neuro Oncology Tissue Repository and the director of the Automated Biomarker Laboratory.
Her conference activities include weekly or monthly conferences with Pathology, Neurology and Neuro-Oncology. She has particular interest in tumor pathology and the weekly consensus review sessions in which all primary brain tumors are discussed, along with cases of complexity or particular interest. This session allows the neuropathology staff to maintain a consistent set of diagnostic criteria and terminology.
She is one of four neuropathologists that diagnose approximately 700 in-house surgical neuropathology cases, and 500 consultation cases per year. In a given year, over 900 intra-operative diagnostic consultations are processed.
Her research interests focus on identifying the underlying molecular changes in the lesions and malformations associated with hereditary brain tumor syndromes in particular, neurofibromatosis 1, neurofibromatosis 2, schwannomatosis, and tuberous sclerosis; and comparative pathology with genetically modified mouse models.
Clinical Interests:
- Autopsy Pathology
- Frozen Section Pathology
- Molecular pathology
- Neuropathology
- Ophthalmic pathology
Treats:
- Adult
Languages:
- French, Hebrew, Italian
Locations
Mass General Pathology
55 Fruit St.
Boston, MA 02114
Phone: 617-643-0800
Medical Education
- MD, University of Milan
- Residency, Memorial Hospital Health Science Centre, St. John's
- Residency, University Hospital Health Science Center Canada
- Fellowship, Massachusetts General Hospital
American Board Certifications
- Anatomic Pathology, American Board of Pathology
- Neuropathology, American Board of Pathology
Accepted Insurance Plans
- Aetna
- Beech Street
- Blue Cross Blue Shield
- Blue Cross Blue Shield Medicare
- Cigna
- Commonwealth Care Alliance
- Coventry
- Fallon Health
- Harvard Pilgrim Health Care
- Humana
- Maine Community Health Options
- Mass General Brigham Health Plan
- MassHealth
- Medicaid CT
- Medicaid ME
- Medicaid NH
- Medicaid RI
- Medicaid VT
- Medicare
- Medicare ACO
- Multiplan
- Railroad Medicare
- Senior Whole Health
- TriCare
- Tufts Health Plan
- United Health Care
- Wellpoint
- WellSense
- WellSense NH
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Research
Our lab's research focuses on identifying the underlying molecular changes in the lesions and malformations associated with hereditary brain tumor syndromes (neurofibromatosis 1, neurofibromatosis 2, schwannomatosis and tuberous sclerosis), and the identification of activated pathways or events that lead to tumor progression. We are now moving from defining the molecular features and understanding the biology to more practical translational research of biomarkers and drug screens.
See details at the Stemmer-Rachamimov Lab.
Publications
-
- Failure to Detect Human Papillomavirus in Focal Cortical Dysplasia Type IIb.
Shapiro KA, McGuone D, Deshpande V, Sadow PM, Stemmer-Rachamimov A, Staley KJ. Ann Neurol. 2015 Apr 20.[Epub ahead of print] - Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. Shankar GM, Taylor-Weiner A, Lelic N, Jones RT, Kim JC, Francis JM, Abedalthagafi M, Borges LF, Coumans JV, Curry WT, Nahed BV, Shin JH, Paek SH, Park SH, Stewart C, Lawrence MS, Cibulskis K, Thorner AR, Van Hummelen P, Stemmer-Rachamimov AO, Batchelor TT, Carter SL, Hoang MP, Santagata S, Louis DN, Barker FG, Meyerson M, Getz G, Brastianos PK, Cahill DP. Acta Neuropathol Commun. 2014 Dec 24;2:167.
- Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. Taylor JW, Dietrich J, Gerstner ER, Norden AD, Rinne ML, Cahill DP,Stemmer-Rachamimov A, Wen PY, Betensky RA, Giorgio DH, Snodgrass K, Randall AE, Batchelor TT, Chi AS. J Neurooncol. 2015 Feb;121(3):557-63. doi: 10.1007/s11060-014-1667-z. Epub 2014 Nov 20.
- Failure to Detect Human Papillomavirus in Focal Cortical Dysplasia Type IIb.
Reviews: Comments and Ratings
Patient Gateway
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
Adolescent and Young Adult (AYA) Cancer Program
The Adolescent and Young Adult Cancer Program was created to optimize the care, outcomes, and experiences of adolescent and young adult patients.
A Top Hospital in America
Mass General is recognized as a top hospital on the U.S. News Best Hospitals Honor Roll for 2024-2025.